Clinical Instructor in Medicine, Dana-Farber Cancer Institute
Hematology
Dr. Douglas J. Weckstein, MD
|
|
Give Review
Douglas Weckstein works in the field of Hematology. He went to medical school at Virginia Commonwealth University School of Medicine. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Douglas Weckstein is a published doctor. He has 12 publications published. The most current publication "ABL oncogenes directly stimulate two distinct target cells in bone marrow from 5-fluorouracil-treated mice." He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus ...
- A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast Cancer.
- Phase II trial of RAD001 and bicalutamide for castration-resistant prostate Cancer.
- Assessment of perceived cost to the patient and other barriers to clinical trial participation.
- Neuroleptic malignant-like syndrome due to cyclobenzaprine?
- Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
- Sunitinib malate for metastatic castration-resistant prostate Cancer following docetaxel-based chemotherapy.
- ABL oncogenes directly stimulate two distinct target Cells in bone marrow from 5-fluorouracil-treated mice.
- Differences in affinities of muscarinic acetylcholine receptor antagonists for Brain and heart receptors.
- The characteristics of I-125 4-IQNB and H-3 QNB in vivo and in vitro.
- Implementing a geriatric assessment in cooperative group clinical Cancer trials: CALGB 360401.
Schools
Virginia Commonwealth University School Of Medicine
New England Med Center Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Tufts Medical Center -
Virginia Commonwealth University School of Medicine
Hospital
-
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1710971684 | |
| NPPES Provider LastName | WECKSTEIN | |
| NPPES Provider FirstName | DOUGLAS | |
| NPPES Provider ZIPCode | 031062504 | |
| NPPES Provider State | NH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 635.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 2.52 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710971684 |
| Last Name Of The Provider | WECKSTEIN |
| First Name Of The Provider | DOUGLAS |
| View All |
Similar Doctors
|
|
Dr. Jeanna H. Walsh, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frederick M. Briccetti, MD |
|
|
Dr. David C. Fisher, MD |